Bass strikes again, targets anaesthetic drug in IPR

Hedge fund manager Kyle Bass has filed another inter partes review (IPR), teaming up with Erich Spangenberg, the former head of patent monetisation firm IPNav, for a second time.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Dr Reddy’s eyes appeal stakes as Boehringer hearing ends

22 October 2026 Questions over what Boehringer’s patents actually proved dominated the final day of the hearing, but a push for a further finding raised the stakes, with a possible appeal threatening to keep Dr Reddy’s off the market even if it won.

Pharma

Amarin and Hikma call time on six-year skinny label fight

22 October 2026 Following a major US Supreme Court win for generics, the landmark dispute has finally come to an end. A new filing brings closure to a case that raised questions over skinny labelling and induced patent infringement.

Pharma

Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility

20 October 2026 In closing arguments last week, the drugmaker urged the UK Patents Court to reject an overly critical approach to plausibility and consider what its patents disclose when read as a whole rather than individually.

More features

Dr Reddy’s eyes appeal stakes as Boehringer hearing ends

Amarin and Hikma call time on six-year skinny label fight

WATCH: Medmix global IP head on building business-focused IP teams

Fish & Richardson hires duo with ‘sophisticated’ tech patent expertise

Fed Circ refuses to rehear Insulet’s $59.4m trade secret loss

Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility

Align Technology notches another win in escalating clear aligner feud

Guardant loses second patent challenge to TwinStrand amid $245m damages fallout

Bass strikes again, targets anaesthetic drug in IPR

More on this story

Editor's picks

Editor's picks

More features